Manuela Grimstein

9PUBLICATIONS
78CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Toxicology (incl. clinical toxicology)Molecular targetsEnvironmental epidemiologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 11, 2025
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting.

Jennifer J Gao, Tatiana M Prowell, Haley Gittleman

|Sep 30, 2024
PBBM Considerations for Base Models, Model Validation, and Application Steps: Workshop Summary Report.

Tycho Heimbach, Flora Musuamba Tshinanu, Kimberly Raines

|Aug 01, 2024
FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation.

Gulsum E Pamuk, Edwin C Y Chow, Alexei C Ionan

|Jun 14, 2024
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer.

Michael I Barbato, Diana Bradford, Yi Ren

|Feb 21, 2024
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer.

Mirat Shah, Hima Lingam, Xin Gao

|Dec 23, 2023
Utility of Physiologically Based Pharmacokinetic Modeling to Investigate the Impact of Physiological Changes of Pregnancy and Cancer on Oncology Drug Pharmacokinetics.

Xinxin Yang, Manuela Grimstein, Michelle Pressly

Pageof 2

Frequent Collaborators

3 joint publications

Richard Pazdur

2 joint publications

Haley Gittleman

2 joint publications

Shenghui Tang

2 joint publications

Ilynn Bulatao